XGN

XGN

USD

Exagen Inc. Common Stock

$10.770-0.310 (-2.798%)

实时价格

Healthcare
Diagnostics & Research
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$11.080

最高价

$11.500

最低价

$10.500

成交量

1.42M

公司基本面

市值

237.0M

所属行业

Diagnostics & Research

国家/地区

United States

交易统计

平均成交量

0.23M

交易所

NGM

货币

USD

52周价格范围

最低价 $2.38当前价 $10.770最高价 $12.23

相关新闻

Analyst Upgrades

BTIG Maintains Buy on Exagen, Raises Price Target to $15

BTIG analyst Mark Massaro maintains Exagen with a Buy and raises the price target from $13 to $15.

查看更多
BTIG Maintains Buy on Exagen, Raises Price Target to $15
GlobeNewswire

Exagen Inc. Reports Strong Q3 2025 Results

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent

查看更多
Exagen Inc. Reports Strong Q3 2025 Results
Analyst Upgrades

Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $15

Canaccord Genuity analyst Kyle Mikson maintains Exagen with a Buy and raises the price target from $11 to $15.

查看更多
Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $15
GlobeNewswire

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology's

查看更多
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
Analyst Upgrades

BTIG Maintains Buy on Exagen, Raises Price Target to $13

BTIG analyst Mark Massaro maintains Exagen with a Buy and raises the price target from $11 to $13.

查看更多
BTIG Maintains Buy on Exagen, Raises Price Target to $13
GlobeNewswire

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the